Lilly Announces Positive Phase III JUVE-BASIS Trial Results for Baricitinib in Juvenile Idiopathic Arthritis

Recently, Eli Lilly and Company released the latest results of the Phase III JUVE-BASIS study on baricitinib for the treatment of juvenile idiopathic arthritis (JIA) in The Lancet. The study results showed that baricitinib demonstrated good efficacy and safety in refractory JIA patients.

Baricitinib is a JAK1/2 inhibitor initially developed by Incyte. In December 2009, Eli Lilly and Company reached a collaboration agreement with Incyte for the co-development and commercialization of baricitinib. To date, baricitinib has been approved for four indications: rheumatoid arthritis (RA), atopic dermatitis (AD), alopecia areata, and COVID-19.

JUVE-BASIS is a randomized, double-blind, placebo-controlled Phase III study designed to evaluate the efficacy and safety of Baricitinib in patients with Juvenile Idiopathic Arthritis (JIA). The study enrolled 220 patients aged 2 to 18 years with extended oligoarticular JIA, polyarticular JIA, enthesitis-related arthritis, or juvenile psoriatic arthritis who had an inadequate response to one or more conventional synthetic or biological disease-modifying antirheumatic drugs (bDMARDs).

JUVE-BASIS Study Design (Reference)

The JUVE-BASIS study was divided into three phases: a 2-week pharmacokinetic/safety assessment (n=29), a 12-week open-label induction period (n=219), and a 32-week double-blind treatment period (n=163). After safety and dose confirmation, patients entered the open-label induction phase and received once-daily oral baricitinib based on age-appropriate dosing. At the end of the open-label induction period, patients with a significant JIA-ACR30 response (i.e., achieving the American College of Rheumatology 30% improvement criteria) were randomized 1:1 to continue receiving either baricitinib or placebo until Week 32 or disease flare.

The data results show that the JUVE-BASIS study has reached its primary endpoint.During the double-blind treatment period, compared with placebo, the time to JIA flare was significantly shorter in patients treated with baricitinib (p<0.0001); furthermore, the proportion of patients experiencing a JIA flare was also significantly lower in the baricitinib group compared with the placebo group.（17.0% vs. 51.0%，p<0.001）。

In terms of safety, baricitinib treatment was well tolerated. During the double-blind treatment period, the incidence of TEAEs in the baricitinib group was 66%, compared to 47% in the placebo group; the incidence of SAEs in the baricitinib group was 5%, compared to 4% in the placebo group.

Juvenile Idiopathic Arthritis (JIA) is a common rheumatic disease in childhood, characterized primarily by chronic synovitis of the joints. Some subtypes can be accompanied by systemic multi-organ dysfunction, making it an important cause of disability and blindness during childhood. Traditional therapeutic drugs for JIA include nonsteroidal anti-inflammatory drugs, corticosteroids, and immunosuppressants, among others. However, in some patients, the condition still cannot be well controlled after using these drugs. In recent years, targeted drugs for treating JIA have emerged, including biologics such as TNF-α antagonists, IL-1R antagonists, IL-6R antagonists, and IL-17 antagonists; small molecule targeted drugs mainly include JAK inhibitors, among others.

References:

https://doi.org/10.1016/S0140-6736(23)00921-2

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position; if you need to reprint, please leave a message or send a notification to the WeChat Official Account backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Exciting Preview

Online Live Streaming & Offline Salon